Why the study?
Do Gly389Arg and Ser49Gly polymorphisms of the β1-adrenoreceptor gene influence cardiac function and cardiovascular complications in normotensive patients with thyrotoxicosis?
Do Gly389Arg and Ser49Gly polymorphisms of the β1-adrenoreceptor gene influence cardiac function and cardiovascular complications in normotensive patients with thyrotoxicosis?
Gly389Arg and Ser49Gly polymorphisms of the β1-adrenoreceptor gene do not significantly impact cardiac function or cardiovascular complications in normotensive patients with thyrotoxicosis.
No significant effects observed; leaves open whether β1-adrenoreceptor genotyping aids risk stratification in thyrotoxicosis.
Human cardiac β 1-AR perform a crucial role in mediating the cardiostimulating effects of norepinephrine. Gly389Arg and Ser49Gly polymorphisms of β 1-adrenoreceptors ( β 1-AR) can influence the cardiovascular prognosis. However, the possible effect of Gly389Arg and Ser49Gly polymorphisms on heart function in thyrotoxicosis has not been studied. We investigated the possible link between Gly389Arg and Ser49Gly polymorphisms and echocardiography parameters in 165 normotensive patients with a thyrotoxicosis without any cardiovascular disorders. Echo-CG was performed according to standard protocol before and during the thyreostatic treatment. Our data demonstrate that both Gly389Arg and Ser49Gly polymorphisms have very moderate influence on the risk of left ventricular hypertrophy and atrial fibrillation with no statistically significant effects on cardiac function and the development of cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Babenko et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: